Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Feb;51(2):783-6.
doi: 10.1128/AAC.00420-06. Epub 2006 Dec 11.

Pharmacokinetics and safety of indinavir in human immunodeficiency virus-infected pregnant women

Jashvant D Unadkat  1 , Diane W Wara, Michael D Hughes, Anita A Mathias, Diane T Holland, Mary E Paul, James Connor, Sharon Huang, Bach-Yen Nguyen, D Heather Watts, Lynne M Mofenson, Elizabeth Smith, Paul Deutsch, Kathleen A Kaiser, Ruth E Tuomala
Affiliations

Pharmacokinetics and safety of indinavir in human immunodeficiency virus-infected pregnant women

Jashvant D Unadkat et al. Antimicrob Agents Chemother. 2007 Feb.

Abstract

Human immunodeficiency virus-infected women (n=16) received indinavir (800 mg three times a day) plus zidovudine plus lamivudine from 14 to 28 weeks of gestation to 12 weeks postpartum. Two women and eight infants experienced grade 3 or 4 toxicities that were possibly treatment related. Indinavir area under the plasma concentration-time curve was 68% lower antepartum versus postpartum, suggesting increased intestinal and/or hepatic CYP3A activity during pregnancy.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Area under the plasma concentration-time curves (AUC0-8) of indinavir in all but two women were lower antepartum versus postpartum. The horizontal solid line represents the arithmetic mean AUC0-8 values for the antepartum and postpartum periods.
See this image and copyright information in PMC

References

    1. AIDS Clinical Trials Group. 1996. Table of grading severity of adult adverse experiences. Division of AIDS, National Institute of Allergy and Infectious Diseases, Rockville, MD.
    1. Back, D., G. Gatti, C. Fletcher, R. Garaffo, R. Haubrich, R. Hoetelmans, M. Kurowski, A. Luber, C. Merry, and C. F. Perno. 2002. Therapeutic drug monitoring in HIV infection: current status and future directions. AIDS 16(Suppl. 1):S5-S37. - PubMed
    1. Bean, P. 2000. HIV's pharmacokinetics, pharmacodynamics, pharmacogenetics, and pharmacogenomics. Am. Clin. Lab. 19:12. - PubMed
    1. Centers For Disease Control and Prevention. 1998. Public Health Service Task Force recommendations for the use of antiretroviral drugs in pregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-1 transmission in the United States. Morb. Mortal. Wkly. Rep. 47:1-20. - PubMed
    1. Choo, E. F., B. Leake, C. Wandel, H. Imamura, A. J. Wood, G. R. Wilkinson, and R. B. Kim. 2000. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab. Dispos. 28:655-660. - PubMed

Publication types